AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

AC Immune S.A.NASDAQ: ACIU

Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025

Accounts receivables declines year over year

Q4 FY2025 accounts receivables of CHF 638.45K fell 97.3% year over year, in line with the -97.3% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Accounts receivables amounted to 24.6% of revenue in FY2025, down 25.1 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -97.3% toward the trailing-twelve-month pace of -97.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 638.45K+251.7% QoQ
Last fiscal yearDec 2025
CHF 877.68K-93.5% YoY
LTMDec 2025
CHF 356.45K-97.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.3%——
1 year-93.5%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

CHF · from the cash flow

Latest · FY2025
877.68K CHF
Year-over-year change
-93.5%

Accounts Receivables vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.3% is the 3rd highest of 4, against a peer median of -96.4%.
  • Accounts receivables amounts to 10.0% of revenue for ACIU, versus a peer median of 3.3%.
ACIU Competitors
Accounts Receivables for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLNSilence Therapeutics plcLTM Mar 2026$8.33M USD——904.4%
CLLSCellectis S.A.LTM Mar 2026$2.24M USD-96.4%-20.9%3.3%
AMRNAmarin Corporation plcLTM Mar 2026$1.05M USD-111.1%—0.5%
ACIUAC Immune S.A.LTM Dec 2025CHF 356.45K CHF-97.3%+13.3%10.0%
MREOMereo BioPharma Group plcLTM Mar 2026$345.69K USD+257.1%—69.1%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 USD———
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ACIU) —-96.4%-20.9%3.3%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.